This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock TALS vs. PRME, IKT, PLX, IZTC, CRTX, ZIVO, CVM, JATT, CLDI, and FNCHShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector. Talaris Therapeutics vs. Its Competitors Prime Medicine Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme ZIVO Bioscience CEL-SCI JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group Talaris Therapeutics (NASDAQ:TALS) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Do insiders & institutionals have more ownership in TALS or PRME? 67.6% of Talaris Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 16.5% of Talaris Therapeutics shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend TALS or PRME? Prime Medicine has a consensus target price of $9.25, suggesting a potential upside of 138.22%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is TALS or PRME more profitable? Talaris Therapeutics' return on equity of -39.93% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Talaris TherapeuticsN/A -39.93% -37.37% Prime Medicine N/A -107.87%-74.97% Which has preferable earnings and valuation, TALS or PRME? Talaris Therapeutics has higher earnings, but lower revenue than Prime Medicine. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalaris TherapeuticsN/AN/A-$73.89M-$1.79-12.68Prime Medicine$3.85M135.79-$198.13M-$1.61-2.41 Does the media refer more to TALS or PRME? In the previous week, Prime Medicine had 4 more articles in the media than Talaris Therapeutics. MarketBeat recorded 4 mentions for Prime Medicine and 0 mentions for Talaris Therapeutics. Prime Medicine's average media sentiment score of 0.92 beat Talaris Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Overall Sentiment Talaris Therapeutics Neutral Prime Medicine Positive Which has more risk & volatility, TALS or PRME? Talaris Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. SummaryPrime Medicine beats Talaris Therapeutics on 12 of the 15 factors compared between the two stocks. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TALS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$970.32M$270.14M$5.60B$9.53BDividend YieldN/AN/A4.71%4.03%P/E Ratio-12.68N/A27.8719.99Price / SalesN/A349.06390.8066.42Price / CashN/A22.4436.3258.75Price / Book5.2410.158.345.79Net Income-$73.89M-$110.10M$3.25B$259.10M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$22.69+0.4%N/A+26.0%$970.32MN/A-12.6884PRMEPrime Medicine3.8528 of 5 stars$4.64+2.4%$9.25+99.4%-31.2%$609.27M$3.85M-2.26234High Trading VolumeIKTInhibikase Therapeutics1.4813 of 5 stars$1.98+2.6%$6.50+228.3%+9.7%$147.20MN/A-0.746Gap UpPLXProtalix BioTherapeutics2.1811 of 5 stars$1.60+1.3%$15.00+837.5%+29.8%$127.37M$59.76M-12.31200IZTCInvizyne TechnologiesN/A$9.25flatN/AN/A$57.83MN/A0.0029Gap UpCRTXCortexymeN/A$1.90+0.5%N/A+135.5%$57.29MN/A-0.6455ZIVOZIVO BioscienceN/A$13.25flatN/A+28.1%$50.58M$15.85K-2.7210CVMCEL-SCI1.0869 of 5 stars$6.29+19.4%N/A-80.6%$33.47MN/A-13.1043News CoveragePositive NewsInsider TradeHigh Trading VolumeJATTJATT AcquisitionN/A$1.68-2.3%N/A-59.2%$28.98MN/A0.003High Trading VolumeCLDICalidi Biotherapeutics0.2632 of 5 stars$0.74+6.2%N/A-58.2%$26.85MN/A0.0038Gap DownFNCHFinch Therapeutics GroupN/A$12.28-0.9%N/A+666.9%$19.72MN/A-1.39190Gap Down Related Companies and Tools Related Companies Prime Medicine Alternatives Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Invizyne Technologies Alternatives Cortexyme Alternatives ZIVO Bioscience Alternatives CEL-SCI Alternatives JATT Acquisition Alternatives Calidi Biotherapeutics Alternatives Finch Therapeutics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TALS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TALS Stock Alerts